Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
21.00
+2.09 (11.02%)
At close: Oct 14, 2025, 4:00 PM EDT
20.83
-0.17 (-0.81%)
After-hours: Oct 14, 2025, 4:43 PM EDT
Spyre Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
65
Market Cap
1.27B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | 886.00K | -1.44M | -61.96% |
Dec 31, 2022 | 2.33M | -16.41M | -87.57% |
Dec 31, 2021 | 18.74M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SYRE News
- 20 hours ago - Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock - GlobeNewsWire
- 1 day ago - Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 9 days ago - Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 - GlobeNewsWire
- 25 days ago - Intelligent Development Could Make Spyre Therapeutics Best In Show - Seeking Alpha
- 5 weeks ago - Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum - GlobeNewsWire
- 5 weeks ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 2 months ago - Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward - Seeking Alpha